Global Alunbrig Market Size By Type (30mg, 50mg), By Application (Hospital, Pharmacy), By Region, And Segment Forecasts, 2023 to 2032

The Global Alunbrig Market was valued at USD 0.36 billion in 2023 and is projected to surpass USD 0.82 billion by 2031, growing at a CAGR of 10.8% during the forecast period (2023–2031). Alunbrig (brigatinib), developed primarily for the treatment of ALK-positive non-small cell lung cancer (NSCLC), is gaining traction due to increasing lung cancer incidence and the growing preference for targeted therapies. Its approval as a second-line therapy following crizotinib failure has strengthened its clinical significance, while ongoing clinical trials are exploring expanded indications and combination therapies.

Drivers:

Rising Lung Cancer Prevalence:

The global burden of NSCLC is rising steadily, particularly among populations exposed to smoking and environmental pollutants. Alunbrig is being increasingly used in the management of ALK-positive NSCLC cases due to its efficacy and tolerability.

Increasing Adoption of Precision Oncology:

The shift from traditional chemotherapy to targeted therapies is driving the market. Alunbrig’s efficacy in targeting ALK gene rearrangements positions it strongly in the precision medicine landscape.

Favorable Clinical Outcomes and Guidelines Inclusion:

Clinical trials such as ALTA-1L have demonstrated promising progression-free survival (PFS) benefits, leading to Alunbrig’s inclusion in clinical guidelines as a recommended option for first- and second-line settings.

Restraints:

High Cost of Treatment:

Alunbrig, like many oncology therapies, comes with a high price tag. The cost of long-term therapy poses affordability challenges in lower- and middle-income regions.

Availability of Competing ALK Inhibitors:

Drugs such as alectinib, ceritinib, and lorlatinib offer strong competition. Payer preference for established first-line therapies may limit Alunbrig’s broader adoption.

Opportunity:

Label Expansion and Combination Trials:

Ongoing clinical research into Alunbrig's effectiveness in earlier stages of lung cancer, or in combination with immunotherapies, could significantly broaden its therapeutic reach.

Emerging Markets Expansion:

Increased healthcare investment and growing cancer awareness in emerging markets provide untapped potential for Alunbrig’s adoption, especially with enhanced diagnostic capabilities for ALK mutations.

Market by System Type Insights:

On the basis of therapy lines, the Second-Line Treatment segment held the dominant market share in 2023. Alunbrig’s approval for use post-crizotinib failure anchors its position here. However, the First-Line Treatment segment is projected to grow at the fastest rate, driven by favorable trial outcomes and the potential for wider regulatory acceptance globally.

Market by End-use Insights:

Hospitals accounted for the largest revenue share in 2023 due to the complex nature of oncology treatment requiring advanced diagnostic and monitoring setups. Oncology centers and specialty clinics are expected to gain momentum as targeted therapy penetration increases, especially in outpatient care models.

Market by Regional Insights:

North America led the global Alunbrig market in 2023, supported by high cancer prevalence, established reimbursement frameworks, and advanced diagnostics. Meanwhile, Asia-Pacific is anticipated to register the fastest growth, propelled by improving healthcare infrastructure, increasing access to ALK testing, and growing cancer awareness in countries like China and India.

Competitive Scenario:

Key players in the Global Alunbrig Market include Takeda Pharmaceutical Company Limited (manufacturer of Alunbrig), Pfizer Inc., Roche Holding AG, Novartis AG, and AstraZeneca plc. Market strategies include label expansions, co-marketing agreements, and active engagement in real-world data studies to boost therapy adoption.

Recent Developments:

In 2023, Takeda launched real-world effectiveness studies across European oncology centers to benchmark Alunbrig’s performance against first-line alectinib.

In 2024, regulatory filings in Latin America and Asia-Pacific markets were expedited to support broader access and first-line therapy use.

Collaborative trials were initiated in 2025, evaluating Alunbrig with immune checkpoint inhibitors in ALK-positive NSCLC patients.

Scope of Work – Global Alunbrig Market

Key Market Developments:

2023: Takeda expands real-world evidence trials in Europe, supporting Alunbrig's comparative effectiveness.

2024: EMA greenlights label update based on ALTA-1L results for frontline usage in ALK-positive NSCLC.

2025: Early access programs launched in India and Brazil for accelerated patient access.

FAQs

1) What is the current market size of the Global Alunbrig Market?

The market was valued at USD 0.36 billion in 2023.

2) What is the major growth driver of the Global Alunbrig Market?

The major growth driver is the increasing prevalence of ALK-positive NSCLC and the adoption of targeted therapies.

3) Which is the largest region during the forecast period in the Global Alunbrig Market?

North America is expected to remain the largest regional market due to advanced diagnostics and treatment accessibility.

4) Which segment accounted for the largest market share in the Global Alunbrig Market?

The Second-Line Treatment segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Alunbrig Market?

Key players include Takeda Pharmaceutical Company Limited, Pfizer Inc., Roche Holding AG, Novartis AG, and AstraZeneca plc.